ArticleMolecular psychiatry2026
Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To date, no objective biochemical markers have been linked to alcohol craving intensity or response to drug treatment for alcohol use disorder (AUD). To address this gap, we aimed to identify potential biomarkers associated with alcohol craving intensity using multi-omics data from the Mayo Clinic acamprosate study-the largest acamprosate trial of its kind and the only one with multi-omics data. In this open-label trial, all 442 participants received acamprosate treatment for three months, during which we collected extensive clinical data, including alcohol consumption and craving intensity. Baseline plasma samples were analyzed using the OLINK "Explore Inflammation" panel, and we employed patient-derived induced pluripotent stem cells (iPSCs) as a functional genomic model. Our findings revealed that baseline craving intensity was the most significant clinical predictor of relapse (p: 9.36E-06). Baseline plasma levels of HSD11B1, an enzyme that converts inactive cortisone to active cortisol, were associated with both craving intensity and acamprosate treatment outcomes. Additionally, baseline plasma cortisol levels showed a positive correlation with craving intensity. Notably, a genome-wide association study (GWAS) for plasma cortisol levels identified significant signals within the KHNYN and CBLN3 gene cluster on chromosome 14. Even more striking, this SNP was also associated with acamprosate treatment outcomes. Functional genomic studies using patient-derived iPSC further suggest that KHNYN and CBLN3 could regulate cortisol metabolism and interferon signaling. In summary, this study leverages multi-omics data from one of the most extensive acamprosate trials to date to identify potential biomarkers for alcohol craving intensity and treatment response.
Indexed as
Identifiers
41741704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.